Business Context and Reporting Period
Company: Milestone Scientific Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: Milestone develops and markets computer-controlled local anesthesia delivery (CCLAD) systems, primarily the STA System and CompuDent, along with disposable handpieces. The company is a smaller reporting company with a history of operating losses.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 |
|---|---|---|
| Total Revenue | $1,402,153 | $2,309,963 |
| Gross Profit | $938,229 (67% margin) | $1,473,001 (64% margin) |
| Net Loss | $(615,885) | $(535,117) |
| Loss Per Share (Basic/Diluted) | $(0.05) | $(0.05) |
| Cash and Cash Equivalents | $237,716 | $745,003 (Dec 31, 2007) |
| Working Capital | $1,551,089 | N/A |
| Line of Credit Outstanding | $1,000,000 | $1,000,000 |
| Accumulated Deficit | $(56,661,800) | $(56,045,915) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by approximately 39% ($907,810) compared to Q1 2007. Product sales dropped 38.6% to $1.39 million, primarily due to a lack of sales by the exclusive domestic distributor and the absence of the initial STA product launch spike seen in 2007.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased by 20% ($364,910) due to reduced marketing and travel costs associated with the STA launch in the prior year. However, stock-based compensation costs increased significantly.
- R&D Decrease: Research and development expenses fell by 73% ($130,247) as the company moved past the initial launch phase of the STA product.
- Cash Burn: Cash and cash equivalents declined by $507,287 during the quarter. Net cash used in operating activities was $407,598, an improvement over the $693,600 used in Q1 2007.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management explicitly states that recurring losses and negative operating cash flows raise substantial doubt about the company's ability to continue as a going concern. The company does not have sufficient cash reserves to meet anticipated obligations for the next twelve months without raising additional capital.
- Capital Needs: The company anticipates a need for higher levels of marketing and sales funding that it currently cannot support. If additional capital cannot be raised, the company may be forced to curtail development or reduce marketing expenses.
- Debt Facility: The company has a $1.0 million line of credit from a stockholder, which was fully utilized as of December 31, 2007. Subsequent to the quarter end (March 31, 2008), this line was increased by $300,000 to $1.3 million.
- Legal Proceedings: The company is engaged in patent litigation with Dr. Milton Hodosh regarding the STA and CompuDent systems. Milestone has filed a declaratory judgment action and counterclaims, asserting non-infringement and invalidity of Dr. Hodosh's patent. The case is in the discovery phase.
- Strategic Focus: Management is refining marketing strategies for the STA System to clarify its utility for all injection types, not just single-tooth anesthesia. International expansion is planned for South Africa and Europe in 2008.
Investor Verification Checklist
- Liquidity Runway: Verify the company's ability to secure additional financing given the explicit "going concern" warning and cash balance of only $237,716.
- Distributor Performance: Assess the performance and commitment of the exclusive domestic distributor (Henry Schein), as domestic sales were heavily impacted by their lack of sales volume.
- Legal Exposure: Monitor the status of the patent infringement lawsuit with Dr. Hodosh, which could result in injunctions or significant damages.
- Stock-Based Compensation: Review the impact of non-cash stock issuances for services and compensation, which totaled over $638,000 in the quarter, on future dilution.
- Debt Terms: Confirm the terms of the stockholder line of credit, including the option to repay in stock and the issuance of warrants, which may affect shareholder value.